Yan Moore

Omega Therapeutics Announces Appointment of Yan Moore, M.D., as Chief Medical Officer

Retrieved on: 
Monday, January 10, 2022

CAMBRIDGE, Mass., Jan. 10, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing platform, today announced the appointment of Yan Moore, M.D., as Chief Medical Officer.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 10, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing platform, today announced the appointment of Yan Moore, M.D., as Chief Medical Officer.
  • Dr. Moore has extensive management, research, translational drug development and medical affairs experience across various pharmaceutical and biotechnology companies.
  • "The OMEGA Epigenomic Programming platform has the potential to provide meaningful, disease modifying treatments to patients and families in need," said Dr. Moore.
  • As a clinician, Dr. Moore spent time at Sapir Medical Center, Meir Hospital and Edith Wolfson Medical Center.